Detalhe da pesquisa
1.
Differences in survival for patients with familial and sporadic cancer.
Int J Cancer;
140(3): 581-590, 2017 Feb 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27759937
2.
Tamoxifen therapy benefit for patients with 70-gene signature high and low risk.
Breast Cancer Res Treat;
166(2): 593-601, 2017 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28776283
3.
Concordance of Immunohistochemistry-Based and Gene Expression-Based Subtyping in Breast Cancer.
JNCI Cancer Spectr;
5(1)2021 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33442660
4.
Family History, Reproductive, and Lifestyle Risk Factors for Fibroadenoma and Breast Cancer.
JNCI Cancer Spectr;
2(3): pky051, 2018 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31360866
5.
Molecular Differences between Screen-Detected and Interval Breast Cancers Are Largely Explained by PAM50 Subtypes.
Clin Cancer Res;
23(10): 2584-2592, 2017 May 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27587435
6.
Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.
J Clin Oncol;
30(21): 2601-8, 2012 Jul 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22711854